表紙
市場調查報告書

人類基因定序全球市場分析和預測:2020-2024年

Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct To Consumer, by Country. With Executive and Consultant Guides. 2020 to 2024

出版商 Howe Sound Research 商品編碼 766998
出版日期 內容資訊 英文 489 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
人類基因定序全球市場分析和預測:2020-2024年 Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct To Consumer, by Country. With Executive and Consultant Guides. 2020 to 2024
出版日期: 2019年11月03日內容資訊: 英文 489 Pages
簡介

本報告分析全球人類基因定序市場,彙整市場及技術定義與概要、各種投入業者和其角色、人類基因定序應用和案例、主要企業簡介、影響市場成長的各種因素分析、技術開發和業務發展趨勢、按應用的市場成長預測、未來展望等情報。

第1章 簡介和市場定義

第2章 市場概要

  • 市場投入者的不同角色
  • 人類基因定序:市場、案例、討論
  • 產業結構

第3章 市場趨勢

  • 成長推動因素
  • 成長阻礙因素
  • 定序儀器

第4章 人類基因定序:近年發展

  • Fluxion Bio:獲得NIH補助以開發NIPT化驗
  • Illumina、Broad Institute:基因體分析軟體合作夥伴
  • Illumina、Adaptive Biotechnologies:在免疫定序的IVD測試合作夥伴
  • Menarini Silicon Biosystems、BlueBee:定序數據分析平台合作夥伴
  • NIH:針對100萬人規模的定序提供Color資金
  • Veritas Genetics:全基因體定序費用降低40%
  • 重症病患的超快速基因定序診斷
  • 透過新血液測試檢測大腸癌症
  • PerkinElmer Genomics:醫囑基因篩選檢測的導入
  • Roche:在癌症檢測的突變剖析軟體方面獲得CE認證
  • PGDx、PathGroup:簽訂共同開發協議、其他

第5章 主要企業簡介

第6章 全球市場規模

  • 市場規模:按應用

第7章 市場規模:按應用

  • 遺傳性基因定序
  • 新生兒基因定序
  • NIPT基因定序
  • 腫瘤基因定序
  • 藥物基因體基因定序
  • D2C基因定序

第8章 未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

OVERVIEW:

Will all newborns receive genetic testing at birth? Why has Direct to Consumer Testing taken a big jump? What's holding the industry back? Where are the over 800 locations that have high throughput sequencing devices?

Our facts and support = Your success.

The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Gene Sequencing Markets - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Gene Sequencing Definition In This Report
    • 1.1.1 Gene Sequencing
    • 1.1.2 Hereditary
    • 1.1.3 Newborn Screening
    • 1.1.4 Non Invasise Prenatal Testing
    • 1.1.5 Oncology
    • 1.1.6 Pharmacogenomic
    • 1.1.7 Direct to Consumer
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for laboratory testing
  • 1.5 Genetic Testing vs. Gene Sequencing
    • 1.5.1 Cost and Pricing Practice
  • 1A Global Listing of Sequencer Installed Base - Location & Contacts
    • 1A.1 Notes to Installed Base Listing

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Instrument Manufacturer
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Sequencing Labs
    • 2.1.10 Audit body
  • 2.2 Human Gene Sequencing -Markets, Examples and Discussion
    • 2.2.1 Inherited Disease - Not what it used to be
      • 2.2.1.1 Clinical and Research Lines Blur
      • 2.2.1.2 Genetic Counselling - Not so simple anymore
      • 2.2.1.3 The Genetic Blizzard - Issues of Access and Payment
    • 2.2.2 Newborn Screening - The Standard of Care
      • 2.2.2.1 Newborn Screening - Do Parents Want to Know?
    • 2.2.3 NIPT - We've Only Just Begun
      • 2.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
      • 2.2.3.2 NIPT in the Future - Beyond Inherited Disease
    • 2.2.4 Oncology - Understanding Two Worlds
      • 2.2.4.1 The Tumor - A Sequence of Sequencing
      • 2.2.4.2 The Tumor - Biopsy and Liquid Biopsy
      • 2.2.4.3 The Human Genome - Predisposition and Prognosis
    • 2.2.5 Pharmacogenomics
      • 2.2.5.1 Sequencing Not the Only Player
      • 2.2.5.2 New Roles for Old Drugs - A Research Bonanza?
    • 2.2.6 Direct To Consumer - More Than Meets the Eye
      • 2.2.6.1 DTC - How Many Segments?
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 The Rise of the Sequencing Lab
    • 2.3.3 Sequencing as a Commodity
    • 2.3.4 Informatics
    • 2.3.5 Instrument Manufacturer Role
    • 2.3.6 Healthcare Industry Impacts - Still Struggling
    • 2.3.7 Can the Healthcare Industry Adapt?
    • 2.3.8 Genetic Counselling as an Industry
    • 2.3.9 Sequencing Adoption and Cannibalization

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 New Diagnoses
    • 3.1.2 Wellness and Prevention
    • 3.1.3 Fertility Technology
    • 3.1.4 Cancer - Screening, Management and Monitoring
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Healthcare Cost Concerns Curtail Growth.
    • 3.2.4 Wellness has a downside
  • 3.3 Sequencing Instrumentation
    • 3.3.1 Instrumentation Tenacity.
    • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
    • 3.3.3 LISTING of CURRENT INSTRUMENT SPECIFICATIONS
    • 3.3.4 Long Reads - Further Segmentation
    • 3.3.5 Linked Reads
    • 3.3.6 New Sequencing Technologies

4. Human Gene Sequencing Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • Fluxion Bio Wins NIH Grant to Develop NIPT Assay
      • Illumina, Broad Institute Collaborate on Genome Analysis Software
      • Illumina, Adaptive Biotechnologies Partner on IVD Test Kits for Immune Sequencing
      • Menarini Silicon Biosystems, BlueBee Partner on Sequencing Data Analysis Platform
      • Paying cash for elective genomic sequencing
      • NIH funds Color ahead of million-person sequencing effort
      • Veritas Genetics slashes price of whole genome sequencing 40% to $600
      • Superfast gene sequencing diagnoses critically ill patients
      • New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
      • PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive
      • Health Management
      • Roche Gets CE Mark for Mutation Profiler Software for NGS Cancer Tests
      • PGDx and PathGroup Enter Co-Development Agreement
      • Newborn genomic sequencing detects unanticipated disease risk factors
      • llumina to Acquire Pacific Biosciences for $1.2 Billion

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Cepheid (now Danaher
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1 Global Market by Application

7. Market Sizes by Application

  • 7.1 Hereditary Gene Sequencing Market
  • 7.2 Newborn Gene Sequencing Market
  • 7.3 NIPT Gene Sequencing Market
  • 7.4 Oncology Gene Sequencing Market
  • 7.5 Pharmacogenomic Gene Sequencing Market
  • 7.6 Direct To Consumer Gene Sequencing Market

8. Vision of the Future of Human Gene Sequencing

Appendices

  • I. United States Medicare System: 2019 laboratory Fees Schedule
  • II Methodology
  • II.1 Authors
  • II.2 Sources

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • Table 3 Lab Spending 2014 to 2024
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Human Gene Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 The Factors Driving Growth
  • Table 9 Factors Limiting Growth
  • Table 10 - Listing of Current NGS Instrument Specifications
  • Table 11 Six New Sequencing Technologies
  • Table 12 Global Market by Application
  • Table 13 Hereditary Segment by Country
  • Table 14 Newborn Segment by Country
  • Table 15 NIPT Segment by Country
  • Table 16 Oncology Segment by Country
  • Table 17 Pharmacogenomic Segment by Country
  • Table 18 Direct To Consumer Segment by Country
  • Table 19 2019 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Clinical Lab Spending 2014 to 2024
  • Figure 2 Gene Sequencing
  • Figure 3 TruSight Germline Panel
  • Figure 4 Historical Cost of Gene Sequencing
  • Figure 5 - Cost To Sequence a Human Genome
  • Figure 6 Application Share by Year
  • Figure 7 Application Segment Growth Rates
  • Figure 8 Segment Share Shifts
  • Figure 9 Hereditary vs. Total Market Growth
  • Figure 10 Newborn vs. Total Market Growth
  • Figure 11 NIPT vs. Total Market Growth
  • Figure 12 Oncology vs. Total Market Growth
  • Figure 13 Pharmacogenomic vs. Total Market Growth
  • Figure 14 Direct To Consumer vs. Total Market Growth
Back to Top